Dr. Bauer on Rovalpituzumab Tesirine in SCLC
October 4th 2016Todd Bauer, MD, associate director, Drug Development, Sarah Cannon Research Institute, discusses the emergence of the novel agent rovalpituzumab tesirine in the treatment of patients with small cell lung cancer in an interview during the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.
Read More
Dr. Bauer on Rovalpituzumab Tesirine in Patients With SCLC
July 5th 2016Todd Bauer, MD, associate director, Drug Development, principal investigator, Sarah Cannon Research Institute, discusses the safety and efficacy of single-agent rovalpituzumab tesirine (Rova-T), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate in recurrent/refractory patients with small cell lung cancer (SCLC).
Read More